Kaplan J - Search Results

1

Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.

Redman BG, Flaherty L, Chou TH, Nakeff A, Pillote K, Kaplan J. Redman BG, et al. Among authors: kaplan j. J Immunother (1991). 1991 Apr;10(2):147-51. doi: 10.1097/00002371-199104000-00009. J Immunother (1991). 1991. PMID: 2043595

2

A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.

Redman BG, Flaherty L, Chou TH, al-Katib A, Kraut M, Martino S, Chen B, Kaplan J, Valdivieso M. Redman BG, et al. Among authors: kaplan j. J Clin Oncol. 1990 Jul;8(7):1269-76. doi: 10.1200/JCO.1990.8.7.1269. J Clin Oncol. 1990. PMID: 2113571

3

Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.

Uberti J, Martilotti F, Chou TH, Kaplan J. Uberti J, et al. Among authors: kaplan j. Blood. 1992 Jan 1;79(1):261-8. Blood. 1992. PMID: 1370206 Free article.

4

TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.

Yamamoto H, Hirayama M, Genyea C, Kaplan J. Yamamoto H, et al. Among authors: kaplan j. J Immunol. 1994 Apr 15;152(8):3842-7. J Immunol. 1994. PMID: 8144953

5

IL-2-activated murine newborn liver NK cells enhance engraftment of hematopoietic stem cells in MHC-mismatched recipients.

Hirayama M, Genyea C, Brownell A, Kaplan J. Hirayama M, et al. Among authors: kaplan j. Bone Marrow Transplant. 1998 Jun;21(12):1245-52. doi: 10.1038/sj.bmt.1701274. Bone Marrow Transplant. 1998. PMID: 9674859

6

Prevention of in vivo alloreactions by adoptive immunotherapy with lymphokine-activated killer cells.

Kaplan J, Uberti J. Kaplan J, et al. Ann N Y Acad Sci. 1991 Dec 30;636:380-2. doi: 10.1111/j.1749-6632.1991.tb33472.x. Ann N Y Acad Sci. 1991. PMID: 1793223 No abstract available.

7

Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.

Azuma E, Yamamoto H, Kaplan J. Azuma E, et al. Among authors: kaplan j. J Immunol. 1989 Sep 1;143(5):1524-9. J Immunol. 1989. PMID: 2668409

8

Role of lymphokine-activated killer cells as mediators of veto and natural suppression.

Azuma E, Kaplan J. Azuma E, et al. Among authors: kaplan j. J Immunol. 1988 Oct 15;141(8):2601-6. J Immunol. 1988. PMID: 3171179

9

Alterations in immune function following head injury in children.

Meert KL, Long M, Kaplan J, Sarnaik AP. Meert KL, et al. Among authors: kaplan j. Crit Care Med. 1995 May;23(5):822-8. doi: 10.1097/00003246-199505000-00008. Crit Care Med. 1995. PMID: 7736738

10

Interferon-gamma receptor polymorphisms determine strain differences in accessibility of activated lymphocyte NK-triggering antigens to recognition by self-reactive NK cells.

Chou SR, Brownell A, Ko MS, Kaplan J. Chou SR, et al. Among authors: kaplan j. Cell Immunol. 2000 Mar 15;200(2):88-97. doi: 10.1006/cimm.1999.1624. Cell Immunol. 2000. PMID: 10753500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,400 results

Search Page

Filters